Introduction
============

In the past decade, indications for liver surgery have changed dramatically. This was mainly due to improvements in surgical technique and new insights in the field of oncology and chemotherapy, which led to larger liver resections.[@b1],[@b2] Despite more extensive preoperative assessment of patients undergoing major liver surgery, post-resectional liver failure still occurs and it remains the most frequent cause of death following major liver surgery.[@b3]--[@b5] Today, preoperative volumetric and, if needed, functional assessment of the liver are the cornerstones in the pursuit of safe resection liver surgery.[@b6]--[@b9]

As primary or secondary liver tumours often are accompanied by weight loss and cachexia, disturbances in body composition and metabolic state are now suggested to be risk factors for the development of major post-operative morbidity and post-resectional liver failure.[@b10] Recently, our group showed that depletion of muscle mass (i.e. sarcopenia) negatively influences total liver volume in patients undergoing liver surgery.[@b11] Several other studies have indicated that disturbances in body composition possibly have negative effects on outcome after liver surgery.[@b10],[@b12]--[@b16] The increased complication rates in patients with body composition disturbances (i.e. sarcopenia, obesity and sarcopenic obesity) might well be partially caused by impaired liver function.

Therefore, the aim of the present study was to explore whether total liver function and volume are influenced by sarcopenia, obesity and sarcopenic obesity in patients undergoing extensive preoperative assessment prior to potential liver surgery.

Materials and methods
=====================

Patients
--------

This study was conducted according to the revised version of the Declaration of Helsinki (October 2008, Seoul). From January 2011 to December 2012, all consecutive patients undergoing a LiMAx[@b6],[@b7] liver function breath test and a CT scan as part of regular preoperative assessment in the Aachen University Hospital were included. Informed consent was obtained in every patient. The decision for LiMAx evaluation was based on clinical indications (such as resection of four or more liver segments and known or suspected fibrosis or cirrhosis) and was made by the responsible surgeons. Patients underwent extensive preoperative laboratory testing, and Child--Pugh[@b17] and model for end-stage liver disease (MELD)[@b18] scores were calculated. Jaundice was defined as a serum bilirubin level greater than 2.5 per decilitre.[@b19] Patients who underwent portal vein embolization (PVE) prior to resection were studied before the PVE procedure.

Methods
-------

### Liver function test

The LiMAx test was used to assess hepatocyte-specific metabolic function. This test is based on metabolization of ^13^C-labelled methacetin (Euriso-top, Saint-Aubin Cedex, France) by the cytochrome P450 1A2 enzyme in the liver.[@b6],[@b7] After intravenous injection, ^13^C-labelled methacetin is instantly metabolized, and the ratio between exhaled ^13^CO~2~ and normal non-enriched background ^12^CO~2~ is registered over a period of 60 min.[@b7]

### Liver volumetry

A 2.4 GHz Intel Core 2 Duo MacBook (Apple Inc., Cupertino, CA, USA) with Osirix® software version 4.1.1 (<http://www.osirix-viewer.com>) was used for volumetric analysis of the liver. Liver contour was manually outlined by one researcher (T.M.L.) on transverse slices of the venous phase of routinely performed preoperative contrast-enhanced CT scans. Total liver volume (TLV) and tumour volume were measured as described earlier.[@b20] The non-tumour total liver volume (ntTLV) was calculated by subtracting tumour volume from TLV.

### Body composition

Presence of sarcopenia was assessed through measurements of skeletal muscle areas by one single researcher (T.M.L.) with the use of the Osirix® programme on contrast-enhanced preoperative (or pre-PVE in case of a PVE) CT scans. A threshold range between −30 and 110 Hounsfield units was set to semiautomatically outline muscle areas at the transversal level of the third lumbar vertebra (L3) as recently described.[@b11] The mean of measurements on two adjacent CT slices at L3 level was used to calculate the L3 skeletal muscle index (L3 MI) by correcting it for height. Sarcopenia was defined as a L3 MI \< 41 cm^2^/m^2^ in women, \<43 cm^2^/m^2^ in men with a body mass index (BMI) of \<25 and \<53 cm^2^/m^2^ in men with a BMI of \>25 as these cut-off values showed an association with mortality.[@b21] The ntTLV--bodyweight ratio (%) was calculated using the following formula: \[ntTLV (mL)/bodyweight (g)\] \* 100%. Body surface area was estimated using the Mosteller formula,[@b22] {\[height (cm) \* weight (kg)\]/3600}^0.5^. Total fat-free body mass (kg) was estimated as 0 · 30 \* (skeletal muscle surface area at L3 in cm^2^) + 6.06.[@b23] Body-fat% was calculated as \[body weight (kg) − fat-free body mass (kg)\]/body weight (kg). Obesity was based on body-fat%; cut-off values for obesity were \>49.6% for women and \>37.5% for men, based on the top two body-fat% quintiles in our study as is conventional for studies evaluating sarcopenic obesity.[@b24]--[@b26] Sarcopenic obesity was defined as the presence of both sarcopenia and obesity according to our definitions.

### Histopathology

One pathologist (N.G.) performed all pathologic examinations. Fibrosis of background liver tissue was classified using the Metavir score, which among others consists of a five-point fibrotic scale.[@b27] The degree of non-alcoholic steatohepatitis (NASH) was analysed using the NASH scoring system (NAS score).[@b28] Finally, sinusoidal dilatation was scored as a four-point scale as a measure of sinusoidal obstruction syndrome.[@b29]

### Outcome after surgery

Post-operative morbidity was graded according to the Dindo--Clavien classification.[@b30] Complications with a grade ≥ 3a were considered major complications. Thirty-day and 90-day mortality were scored.

### Statistical analysis

Data were analysed with SPSS version 18.0 (SPSS Inc., Chicago, IL) and Prism 5.0 for Macintosh (Graphpad software, Inc, San Diego, CA, USA). The data were expressed as median (range). Chi-square tests were used to analyse categorical data while continuous data were analysed with Mann--Whitney *U* tests. A level of *P* \< 0.05 was considered statistically significant. Correlations between body composition factors and liver function or ntTLV were performed in patients with relatively healthy livers, that is, livers without cirrhosis (Metavir fibrotic scale Stage 4[@b27]), NASH (NAS score ≥ 5[@b28]) or severe sinusoidal dilatation (sinusoidal dilatation score = 3[@b29]). Also, patients without pathologic examination of liver tissue were excluded for correlation analysis. Correlations were calculated with Pearson\'s test. The resulting regression line was described as a linear equation, and the correlation coefficient (*r*) was calculated. Relevant clinicopathologic variables associated with liver function were examined using univariable and, where applicable, multivariable linear regression. For the multivariable models, a univariable inclusion criterion of *P* ≤ 0.15 was used.

Results
-------

### Patients

A total of 80 patients were included in the present study. The patient characteristics, body composition and liver-related measurements are presented in detail in *Tables* [1](#tbl1){ref-type="table"} and [2](#tbl2){ref-type="table"}. Indications for potential liver resection were mostly cholangiocarcinoma (*n* = 28, 35.0%), colorectal liver metastases (*n* = 24, 30.0%) and hepatocellular carcinoma (*n* = 15, 18.8%).

###### 

Patient characteristics

  Variables, median (range)       All *n* = 80        Male *n* = 51       Female *n* = 29     *P*
  ------------------------------- ------------------- ------------------- ------------------- ---------
  Patient characteristics                                                                     
  Median age (years)              66 (28--82)         67 (28--82)         64 (29--76)         0.289
  Percentage with ASA 3/4         53.9                51.1                58.6                0.521
  Patients with PVE (%)           34 (42.5)           19 (37.3)           15 (51.7)           0.208
  Weight (kg)                     80 (47--134)        82 (52-109)         72 (47--134)        0.032
  Height (cm)                     174 (155--205)      176 (160--205)      165 (155--180)      \<0.001
  BMI (kg/m^2^)                   24.9 (18.7--46.4)   24.6 (20.2--37.7)   27.3 (18.7--46.4)   0.837
  BMI \>30 kg/m^2^ (%)            14 (17.5)           5 (9.8)             9 (31.0)            0.016
  Child--Pugh grade                                                                           
   Percentage with A              82.1                83.7                79.3                0.627
   Percentage with B              17.9                16.3                20.7                0.627
  MELD score                      7 (6--20)           7 (6--20)           7 (6--19)           0.758
  Indication (%)                                                                              
  Colorectal liver metastases     24 (30.0)           15 (29.4)           9 (31.0)            0.879
  Other metastases                6 (7.5)             3 (5.9)             3 (10.3)            ---
  Hepatocellular carcinoma        15 (18.8)           14 (27.5)           1 (3.4)             0.008
  Cholangiocarcinoma              28 (35.0)           16 (31.4)           12 (41.4)           0.367
  Gallbladder carcinoma           1 (1.3)             0 (0.0)             1 (3.4)             ---
  Benign lesion                   5 (6.3)             2 (3.9)             3 (10.3)            ---
  Living donor liver transplant   1 (1.3)             1 (2.0)             0 (0.0)             ---

ASA, American society of anesthesiologists; PVE, portal vein embolization; BMI, body mass index.

###### 

Body composition and liver-related measurements

  Variables, median (range)                                                                       All *n* = 80        Men *n* = 51        Women *n* = 29      *P*
  ----------------------------------------------------------------------------------------------- ------------------- ------------------- ------------------- ---------
  Body composition                                                                                                                                            
  L3 MI (cm^2^/m^2^)                                                                              45.3 (28.7--71.9)   50.7 (31.9--68.3)   41.6 (28.7--71.9)   \<0.001
  Sarcopenia (%)                                                                                  31 (38.8)           18 (35.3)           13 (44.8)           0.400
  Fat-free body mass (kg)                                                                         47.3 (31.7--75.9)   54.2 (37.7--67.4)   39.8 (31.7--75.9)   \<0.001
  Fat mass (kg)                                                                                   29.0 (1.9--86.0)    28.6 (1.9--45.6)    29.2 (8.3--86.0)    0.296
  Body fat (%)                                                                                    36.5 (2.9--64.2)    34.8 (2.9--49.7)    43.5 (17.5--64.2)   0.001
  Obesity (%)                                                                                     32 (40.0)           21 (41.2)           11 (37.9)           0.776
  Sarcopenic obesity                                                                              18 (22.5)           15 (29.4)           3 (10.3)            0.050
  Body surface area (m^2^)                                                                        1.9 (1.4--2.5)      2.0 (1.5--2.4)      1.81 (1.42--2.52)   0.001
  Liver volume                                                                                                                                                
  Total liver volume (mL)                                                                         1680 (1067--3883)   1844 (1142--3883)   1537 (1067--2871)   0.003
  Tumour volume (mL)                                                                              59 (0--2002)        67 (0--2002)        30 (0--290)         0.159
  Non-tumour TLV (mL)                                                                             1571 (869--2852)    1721 (1052--2708)   1477 (869--2852)    0.017
  Liver function                                                                                                                                              
  LiMAx value (µg/kg/h)                                                                           326 (95--684)       337 (188--594)      301 (95--684)       0.086
  LiMAx/ntTLV (µg/kg/h/mL)                                                                        0.20 (0.06--0.47)   0.19 (0.10--0.47)   0.20 (0.06--0.44)   0.908
  Laboratory testing (normal)                                                                                                                                 
  Bilirubin (mg/dL) (1.2)                                                                         0.7 (0.2--14.3)     0.7 (0.2--5.6)      0.7 (0.3--14.3)     0.540
  ALT (U/L) (50)                                                                                  32 (15--358)        34 (15--164)        32 (16--358)        0.829
  AST (U/L) (38)                                                                                  46 (14--224)        43 (16--211)        49 (14--224)        0.423
  INR (ratio)                                                                                     1.04 (0.82--1.45)   1.05 (0.82--1.45)   1.04 (0.90--1.24)   0.338
  C-reactive protein (mg/L) (\<5)                                                                 10 (1--187)         9 (1--187)          11 (1--172)         0.208
  Creatinin (mg/dL) (0.6--1.1)                                                                    0.9 (0.5--3.8)      0.9 (0.5--3.8)      0.7 (0.5--1.5)      \<0.001
  Albumin (g/L) (35--52)                                                                          36.0 (19.5--45.8)   36.5 (19.5--45.8)   35.8 (22.6--42.7)   0.379
  Background liver                                                                                                                                            
  Metavir                                                                                         1 (0--6)            1 (0--6)            1 (0--4)            0.242
   Percentage cirrhosis (fibrosis score = 4)                                                      8.3                 13.2                0.0                 ---
  NAS                                                                                             1 (0--4)            1 (0--4)            1 (0--4)            0.435
   Percentage severe steatosis (NAS ≥ 5)                                                          0.0                 0.0                 0.0                 ---
  Sinusoidal dilatation score                                                                     0 (0--3)            0 (0--3)            0 (0--3)            ---
   Percentage severe dilatation (Grade 3)                                                         5.3                 5.7                 4.5                 0.663
   Percentage with severe background liver disease (Cirrhosis or NAS ≥ 5 or dilatation Grade 3)   10.5                14.3                4.5                 0.243

L3 MI, L3 skeletal muscle index; AST, aspartate transaminase; ALT, alanine transaminase; ntTLV, non-tumour total liver volume; NAS, non-alcoholic fatty liver disease (NAFLD) activity score.

### Influence of sarcopenia on liver volume and function

The median L3 MI was 50.7 (31.9--68.3) cm^2^/m^2^ in men and 41.6 (28.7--71.9) cm^2^/m^2^ in women. Based on the predefined criteria, 18 (35.3%) men and 13 (44.8%) women were sarcopenic (*Table* [2](#tbl2){ref-type="table"}). *Table* [3](#tbl3){ref-type="table"} shows the features associated with sarcopenia, obesity and sarcopenic obesity. The median preoperative LiMAx value and non-tumour TLV were 326 (95--684) µg/kg/h and 1571 (869--2852) mL, respectively (*Table* [2](#tbl2){ref-type="table"}). No statistically significant difference in liver function was observed between patients with or without sarcopenia \[327 (95--684) µg/kg/h and 324 (125-594) µg/kg/h, respectively, *P* = 0.917\]. Sarcopenic patients also had a comparable ntTLV compared with patients without sarcopenia \[1518 (869--2581) vs. 1678 (1052--2852) mL, *P* = 0.215\] (*Table* [3](#tbl3){ref-type="table"}).

###### 

Features associated with sarcopenia, obesity and sarcopenic obesity

                                          Sarcopenia                              Obesity                       Sarcopenic obesity                                                      
  --------------------------------------- ------------------- ------------------- --------- ------------------- -------------------- --------- -------------------- ------------------- -------
  Median age (years)                      65 (28--80)         67 (34--82)         0.277     65 (28--80)         66 (37--82)          0.180     65 (28--80)          72 (43--82)         0.029
  Sex, number of men (%)                  33 (67.3)           18 (58.1)           0.400     30 (62.5)           21 (65.6)            0.776     36 (58.1)            15 (83.3)           0.050
  BMI (kg/m^2^)                           26.0 (19.6--46.4)   24.2 (18.7--33.0)   0.016     23.6 (18.7--32.1)   28.6 (21.8--46.4)    \<0.001   24.3 (18.7--46.4--   26.6 (21.8--33.0)   0.324
  Child--Pugh Grade A                     83.7                79.3                0.627     85.4                76.7                 0.327     85.5                 68.8                0.120
  Child--Pugh Grade B                     16.3                20.7                0.627     14.6                23.3                 0.327     14.5                 31.3                0.120
  MELD score                              7 (6--20)           7 (6--19)           0.648     7 (6--20)           9 (6--19)            0.015     7 (6--20)            8 (6--19)           0.093
  Liver volume                                                                                                                                                                          
  Total liver volume (mL)                 1762 (1111--3883)   1578 (1067--3290)   0.127     1592 (1067--3883)   1831 (1142--3290)    0.084     1656 (1067--3883)    1768 (1142--3290)   0.637
  Tumour volume (mL)                      28 (0--2002)        63 (0--709)         0.659     50 (0--2002)        72 (0--709)          0.481     50 (0--2002)         72 (0--709)         0.627
  Non-tumour TLV (mL)                     1678 (1052--2852)   1518 (869--2581)    0.215     1533 (869--2852)    1694 (1116--2685)    0.079     1562 (869--2852)     1638 (1116--2581)   0.541
  Non-tumour TLV--body weight ratio (%)   2.02 (1.31--3.22)   2.28 (1.34--3.19)   0.181     2.24 (1.43--3.22)   1.97 (1.31--3.19)    0.062     2.06 (1.31--3.22)    2.16 (1.34--3.19)   1.000
  Liver function                                                                                                                                                                        
  LiMAx value (µg/kg/h)                   324 (125--594)      327 (95--684)       0.917     358 (96--684)       295 (95--508)        0.018     333 (96--684)        313 (95--490)       0.378
  LiMAx/ntTLV (µg/kg/h/mL)                0.19 (0.06--0.47)   0.21 (0.07--0.44)   0.707     0.22 (0.06--0.47)   0.17 (0.07--0.32)    0.004     0.20 (0.06--0.47)    0.18 (0.07--0.32)   0.246
  Laboratory testing (normal)                                                                                                                                                           
  Bilirubin (mg/dL) (\<1.2)               0.6 (0.2--14.3)     0.8 (0.3--5.6)      0.356     0.6 (0.2--4.3)      0.8 (0.3--14.3)      0.140     0.6 (0.2--14.3)      0.8 (0.3--5.6)      0.162
  ALT (U/L) (\<50)                        35 (15--358)        32 (15--234)        0.615     32 (15--234)        39 (15--358)         0.516     36 (15--358)         29 (15--121)        0.341
  AST (U/L) (\<38)                        45 (14--224)        46 (15--150)        0.311     45 (19--211)        49 (14--224)         0.965     46 (14--224)         40 (15--150)        0.313
  INR (ratio)                             1.06 (0.82--1.24)   1.04 (0.90--1.45)   0.700     1.03 (0.82--1.19)   1.06 (0.90--1.45)    0.038     1.04 (0.82--1.24)    1.05 (0.90--1.45)   0.190
  C-reactive protein (mg/L) (\<5)         9 (1--172)          11 (1--187)         0.107     8 (1--95)           19 (1--187)          0.007     9 (1--172)           14 (1--187)         0.034
  Creatinine (mg/dL) (0.6--1.1)           0.9 (0.6--3.8)      0.8 (0.5--2.3)      0.130     0.8 (0.5--3.8)      0.9 (0.5--2.3)       0.623     0.8 (0.5--3.8)       0.9 (0.5--2.3)      0.373
  Albumin (g/L) (35--52)                  36.7 (24.3--45.8)   35.1 (19.5--45.8)   0.138     36.3 (22.6--45.8)   35.7 (19.5--43.1)    0.693     36.6 (22.6--45.8)    35.1 (19.5--41.7)   0.313

BMI, body mass index; ntTLV, non-tumour total liver volume.

### Influence of obesity on liver volume and function

According to our cut-off body-fat% values for obesity, 11 (37.9%) women and 21 (41.2%) men were obese (*Table* [2](#tbl2){ref-type="table"}). The L3 MI in women was comparable between the two groups. On the contrary, in obese men, the L3 MI was significantly smaller compared to that of non-obese men \[42.9 (31.9--68.3) cm^2^/m^2^ vs. 53.4 (41.3--67.7) cm^2^/m^2^, *P* \< 0.001\]. There was a trend towards larger liver volume in obese patients, with an ntTLV of 1694 (1116--2685) mL in obese and 1533 (869--2852) mL in non-obese patients (*P* = 0.079). Median liver function, as determined by LiMAx, was reduced in obese patients \[295 (95--508) vs. 358 (96-684) µg/kg/h, *P* = 0.018\]. Moreover, the median liver function per millilitre ntTLV was significantly smaller in obese patients \[0.17 (0.07--0.32) vs. 0.22 (0.06--0.47), *P* = 0.004\] (*Table* [3](#tbl3){ref-type="table"}).

### Influence of sarcopenic obesity on liver volume and function

Eighteen (22.5%) patients met the criteria for sarcopenic obesity, and sarcopenic-obese patients were predominantly male (83.3%) (*Table* [2](#tbl2){ref-type="table"}). Sarcopenic-obese patients were older than patients without sarcopenic obesity \[72 (43--82) vs. 65 (28--80), *P* = 0.029\]. NtTLV and LiMAx values were comparable between patients with and without sarcopenic obesity (*Table* [3](#tbl3){ref-type="table"}).

### Correlations between liver function, liver volume and body composition

Because of irresectable disease, histopathologic examination was not performed in 23 (28.8%) patients. Another six (10.5) patients had severe background liver disease and were also excluded for assessing possible correlations between liver volume, liver function and body composition (*Figures* [1](#fig01){ref-type="fig"} and [2](#fig02){ref-type="fig"}). Therefore, 51 (63.8%) patients without severe background liver disease were analysed. We found no correlation between the LiMAx test and ntTLV (*r* = 0.06, *P* = 0.679) (*Figure* [1](#fig01){ref-type="fig"}). Weight (*r* = −0.40*, P* = 0.003), body surface area (*r* = −0.32, *P* = 0.023), estimated body-fat% (*r* = −0.43, *P* \< 0.002) and BMI (*r* = −0.47, *P* \< 0.001) showed a weak but significant negative correlation with the LiMAx test outcome. No correlation was found between the LiMAx test and L3 MI (*r* = 0.09, *P* = 0.550) or fat-free body mass (*r* = 0.09, *P* = 0.538) (*Figure* [2](#fig02){ref-type="fig"}). A significant but weak correlation between the L3 MI and ntTLV was found (*r* = 0.41, *P* = 0.003). Moreover, fat-free body mass (*r* = 0.60, *P* \< 0.001), body surface area (*r* = 0.66, *P* \< 0.001), weight (*r* = 0.58, *P* \< 0.001), height (*P* = 0.60, *r* \< 0.001) and BMI (*r* = 0.29, P = 0.042) were all weak but significantly correlated with ntTLV (*Figure* [2](#fig02){ref-type="fig"}).

![Correlation between non-tumour total liver volume (TLV) and liver function (LiMAx).](jcsm0006-0155-f1){#fig01}

![Correlation between, on one hand, non-tumour total liver volume (TLV) (left) and, on the other hand, LiMAx values (right) and L3 skeletal muscle index, fat-free body mass, body-fat%, body surface area, weight and body mass index.](jcsm0006-0155-f2){#fig02}

### Histology

Cirrhosis was present in 8.3% of all patients, and all were men. None of the patients had NASH (*Table* [2](#tbl2){ref-type="table"}). However, 21.1% of the patients had borderline NASH (NAS = 3--4). Of the non-obese and obese, 13.9% and 38.1% were considered as having borderline NASH (*P* = 0.036). Obese patients also showed a significantly higher preoperative C-reactive protein level \[19 (1--187) vs. 8 (1--95) mg/L, *P* = 0.007\] (*Table* [3](#tbl3){ref-type="table"}). Severe sinusoidal dilatation as an indication for sinusoidal obstruction syndrome was present in 5.3% of the patients.

### Predictors of decreased liver function LiMAx value

After univariable analysis, seven variables were considered significant negative prognostic factors for LiMAx liver function values, namely BMI (*P* = 0.001), obesity (*P* = 0.013), fat mass (*P* \< 0.001), body-fat% (*P* \< 0.001), body surface area (*P* = 0.022), INR (International Normalized Ratio) (*P* = 0.012) and sinusoidal dilatation (*P* = 0.019). One additional borderline significant (*P* ≤ 0.15) variable was selected for multivariable analysis, namely female sex (*P* = 0.118) (*Table* [4](#tbl4){ref-type="table"}). Because of possible collinearity with body-fat%, five (borderline) significant negative prognostic factors were excluded for multivariable analysis, that is, BMI, obesity, fat mass, body surface area and NAS score. Using multivariable analysis, only body-fat% was identified as an independent negative prognostic factor influencing the liver function with a regression coefficient (standard error) of −3.2 (1.2), *P* = 0.011. Presence of chemotherapy-induced sinusoidal dilatation also showed a tendency to decrease liver function with a regression coefficient of −34.4 (17.7), *P* = 0.057.

###### 

Univariable and multivariable analysis of factors influencing LiMAx liver function values

                                                             Univariable      Multivariable                   
  ---------------------------------------------------------- ---------------- --------------- --------------- -------
  Age (years)                                                −0.1 (1.1)       0.952                           
  Female sex                                                 −43.6 (27.6)     0.118           −19.0 (31.0)    0.543
  Liver volume (100 mL)                                      −1.1 (3.1)       0.730                           
  Body mass index[a](#tf4-1){ref-type="table-fn"}            −8.3 (2.4)       0.001                           
  Obesity[a](#tf4-1){ref-type="table-fn"}                    −67.0 (26.5)     0.013                           
  Fat-free body mass (kg)                                    1.3 (1.3)        0.330                           
  Fat mass (kg)[a](#tf4-1){ref-type="table-fn"}              −3.7 (0.9)       \<0.001                         
  Body-fat%                                                  −4.0 (1.0)       \<0.001         −3.2 (1.2)      0.011
  Body surface area (m^2^)[a](#tf4-1){ref-type="table-fn"}   −139.8 (59.8)    0.022                           
  Sarcopenia                                                 −6.2 (27.7)      0.823                           
  L3 index (cm^2^/m^2^)                                      1.4 (1.5)        0.357                           
  Sarcopenic obesity                                         −38.8 (32.0)     0.229                           
  AST (U/L)                                                  0.1 (0.3)        0.659                           
  ALT (U/L)                                                  0.1 (0.2)        0.691                           
  Bili (mg/dL)                                               −6.1 (7.6)       0.422                           
  INR (ratio)                                                −366.3 (142.7)   0.012           −53.9 (177.5)   0.763
  Albumin (g/L)                                              −0.2 (2.5)       0.936                           
  Child--Pugh grade                                          1.9 (16.9)       0.909                           
  MELD score                                                 −3.9 (4.5)       0.388                           
  Metavir score                                              −1.7 (8.9)       0.846                           
  NAS score[a](#tf4-1){ref-type="table-fn"}                  −22.7 (11.4)     0.053                           
  Sinusoidal dilatation                                      −44.9 (18.5)     0.019           −34.4 (17.7)    0.057

SE, standard error; NAS, non-alcoholic steatohepatitis.

Excluded from multivariable analysis due to possible collinearity.

### Outcome after liver resection

Complications and survival were evaluated in 57 (71.2%) patients who had undergone liver resection. Complications and major complications occurred in 19 (33.3%) and 17 (29.8%) patients, respectively. Most frequent complications were intra-abdominal abscess (*n* = 8, 14.0%), bile leakage (*n* = 7, 12.3%), biloma (*n* = 4, 7.0%), sepsis (*n* = 4, 7.0%) and intra-abdominal haemorrhage (*n* = 3, 5.3%). One patient developed post-resectional liver failure (1.8%), and another patient developed hepatic encephalopathy (1.8%). There were no differences in major complication rates between sarcopenic and non-sarcopenic patients (*P* = 0.392), obese and non-obese (*P* = 0.530) and patients with and without sarcopenic obesity (*P* = 0.765). Thirty-day and 90-day mortality rates were 3.5% (*n* = 2) and 10.5% (*n* = 6). There were also no significant differences in 90-day mortality rates between patients with and without sarcopenia (*P* = 0.624), obesity (*P* = 0.486) or sarcopenic obesity (*P* = 0.487).

Discussion
==========

This study aimed to assess how liver function and volume relate to sarcopenia, obesity and sarcopenic obesity in patients undergoing extensive preoperative assessment prior to potential liver surgery. We showed that sarcopenic and sarcopenic-obese patients did not have diminished liver function compared with patients without sarcopenia or sarcopenic obesity, evidenced by comparable LiMAx values prior to surgery. Obese patients however showed significantly reduced LiMAx values compared with patients without obesity, and body-fat% was identified as an independent negative factor affecting liver function. Moreover, there were significant negative correlations between the LiMAx values and body-fat%, body surface area, weight and BMI, which confirmed that obesity influenced liver function. Differences in ntTLV between sarcopenic and non-sarcopenic, obese and non-obese and sarcopenic-obese and patients without sarcopenic obesity did not reach statistical significance.

Recently, we demonstrated that liver volume was associated with the L3 MI, whereby sarcopenic patients had smaller ntTLVs compared with patients without sarcopenia.[@b11] In the present study, we found comparable ntTLVs in patients with and without sarcopenia. Nevertheless, the L3 MI was correlated with ntTLV, indicating that muscle wasting is somehow associated with smaller livers. As only patients at risk of developing post-operative liver failure (i.e. large resections) underwent a LiMAx test, a selection bias may have influenced our findings. Whereas the majority of patients in our previous study suffered from colorectal cancer liver metastases, more patients with intrahepatic cholangiocarcinoma or Klatskin tumours were included in the present study. The difference in metabolic behaviour could explain the absence of a significant difference between the ntTLVs of sarcopenic and non-sarcopenic patients and lower correlation coefficient between L3 MI and liver volume in the present study (*r* = 0.41 vs. *r* = 0.64 in the previous study). This study also assessed (LiMAx) liver function values in relation with sarcopenia. The present data do not support the idea that the increased post-operative morbidity, earlier recurrence and shorter survival in sarcopenic patients[@b10],[@b12],[@b16] could be explained by a decline in preoperative liver function. However, sarcopenia or muscle wasting remains an important factor negatively influencing outcome through hypercatabolism, hypoanabolism and, as a result, reduced reserves.

Only few studies have been performed on the effect of obesity on morbidity, overall survival and disease-free survival in the surgical treatment of primary or secondary liver tumours. Recently, Cauchy *et al.* showed that the metabolic syndrome even in absence of overt steatosis adversely affected outcome.[@b14] Also, in other fields of oncologic surgery, obesity has been identified as an important factor affecting outcome.[@b31]--[@b34] In the present study, body-fat%, body surface area, BMI and weight all showed a significant negative correlation with liver function LiMAx values. Moreover, body-fat% was identified as an independent factor negatively affecting the liver function. The significantly decreased LiMAx values in obese patients were accompanied by an increase in borderline NASH as could be expected.[@b35],[@b36] We showed a trend that obese patients had larger livers and a positive correlation between liver volume and bodyweight, BMI and body surface area. Thus, obese patients have larger, although less functioning, livers probably due to deposition of fat, presumably increasing the risk of developing morbidity.

We found no disadvantageous consequences of sarcopenic obesity on liver volume or function. This is probably due to the small number of sarcopenic-obese patients and the heterogeneity of the indications for liver resection. However, it may be that sarcopenic-obese patients have an increased risk of post-operative morbidity as sarcopenia and obesity independently of one another proved to be risk factors for post-operative complications.[@b10],[@b14],[@b16] Differences in complication and mortality could however not be confirmed in this study, but this may relate to the sample size.

Body composition features have been calculated based on preoperative CT scans, body weight and length, and CT scanning is considered the gold standard for estimating muscle mass or lean body mass.[@b37] The use of body-fat% instead of BMI might be a better method of defining obesity as it prevents that muscular patients (with a BMI of \>30) are incorrectly indicated as obese. Moreover, body-fat% is able to identify obesity in thin patients. The sample size and heterogeneity of our population are relative drawbacks of our study. Therefore, further investigations of the influence of body composition on short-term and long-term outcome after liver surgery are of major importance.

In conclusion, sarcopenia and sarcopenic obesity did not seem to influence liver volume or function negatively. However, obese patients have larger but less functional livers compared with those of non-obese patients. This indicates dissociation of function and volume most likely due to deposition of fat. Moreover, body-fat% seemed to be an independent factor affecting liver function negatively. The influence of obesity on morbidity after liver resection should therefore be taken into account as a part of routine preoperative assessment to prevent post-resectional liver failure especially in centres were no standard liver function evaluation is performed before major liver surgery.
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